Clinical pharmacology of antihypertensive therapy for the treatment of hypertension in CKD

Research output: Contribution to journalArticle

6 Scopus citations


CKD is common and frequently complicated with hypertension both predialysis and in ESKD. As a major modifiable risk factor for cardiovascular disease in this high-risk population, treatment of hypertension in CKD is important. We review the mechanisms and indications for themajor classes of antihypertensive drugs, including angiotensinconverting enzyme inhibitors, angiotensin II receptor blockers, β-adrenergic blocking agents, dihydropyridine calcium channel blockers, thiazide diuretics, loop diuretics, mineralocorticoid receptor blockers, direct vasodilators, and centrally acting α-agonists. Recent evidence suggests that β-adrenergic blocking agents may have a greater role in patients on dialysis and that thiazide diuretics may have a greater role in patients with advanced CKD. Weconclude with sharing our general prescribing algorithm for both patientswith predialysis CKD and patients with ESKD on dialysis.

Original languageEnglish (US)
Pages (from-to)757-764
Number of pages8
JournalClinical Journal of the American Society of Nephrology
Issue number5
StatePublished - May 7 2019


ASJC Scopus subject areas

  • Epidemiology
  • Critical Care and Intensive Care Medicine
  • Nephrology
  • Transplantation

Cite this